Clinical Trials Logo

Agitation Aggression in Dementia clinical trials

View clinical trials related to Agitation Aggression in Dementia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00145691 Completed - Clinical trials for Agitation Aggression in Dementia

The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)

Start date: September 2005
Phase: Phase 3
Study type: Interventional

We intend to conduct a phase III b trial to verify Oxcarbazepine's effect in agitation and aggression in patients with dementia. We designed the study as a randomized, double-blind, placebo-controlled multi center trial. Hundred patients will be included. The treatment period will be eight weeks, with a further follow up of four weeks. The primary outcome measure will be the reduction in aggression and agitation as measured by means of NPI-NH-subscale agitation / aggression (Neuropsychiatric Inventory, Nursing Home Version). Secondary outcomes are reduction in aggression as measured by BARS (Behavior Agitation Rating Scale)and reduction in the burden to health-care personnel as measured by NPI-NH.